Amgen Inc. (AMGN)

222.95
NASDAQ : Health Technology
Prev Close 225.59
Day Low/High 221.17 / 224.93
52 Wk Low/High 166.30 / 244.99
Avg Volume 2.21M
Exchange NASDAQ
Shares Outstanding 594.18M
Market Cap 134.04B
EPS 12.70
P/E Ratio 17.33
Div & Yield 6.40 (2.47%)

Latest News

3 Boomer-Inspired Drug Plays With Dividend Appeal

3 Boomer-Inspired Drug Plays With Dividend Appeal

Bristol-Myers Squibb, Amgen and Abbott Labs all recently raised their dividends and should prosper amid the aging population.

Amgen Gets Shot in the Arm, Could Bounce Up in Months Ahead

Amgen Gets Shot in the Arm, Could Bounce Up in Months Ahead

AMGN appears to have taken a turn for the better and is now looking at targets of $254 and $270.

RMPIA Lags in November, but Trounces S&P 500 for Quarter, Year So Far

RMPIA Lags in November, but Trounces S&P 500 for Quarter, Year So Far

Now, many Real Money Post Industrial Average stocks should see a boost from the holiday splurge by shoppers.

News While You Slept, Semi Tough and Updates on Amgen and Splunk: Market Recon

News While You Slept, Semi Tough and Updates on Amgen and Splunk: Market Recon

Also, Fed Chairman Powell says there are no plans for a U.S. digital currency (for now), plus Tesla's electric pickup.

Real Money Post Industrial Average Exits October on Top

Real Money Post Industrial Average Exits October on Top

The RMPIA's 3.8% jump even beat the Nasdaq Composite Index's 3.7% October climb.

Drug Companies Are a Political Football, Trading Amgen: Market Recon

Drug Companies Are a Political Football, Trading Amgen: Market Recon

The nation enters an electoral season. The drug companies for the most part, have no friends on either side of the aisle.

We Prescribe Amgen to Treat Your Portfolio

We Prescribe Amgen to Treat Your Portfolio

According to the charts, the drugmaker should break out to new highs.

Jim Cramer: Drug Stocks Are Too Cheap

Jim Cramer: Drug Stocks Are Too Cheap

These stocks are priced for total imperfection. That's just what you want.

Sussing the Fed -- Plus Apple, Amgen and Other Earnings: Market Recon

Sussing the Fed -- Plus Apple, Amgen and Other Earnings: Market Recon

Markets are watching what Fed Chair Powell will signal for future rate cuts during this afternoon's FOMC rate decision.

6 Market Winds of Change, Trading Beyond Meat, GrubHub Earnings: Market Recon

6 Market Winds of Change, Trading Beyond Meat, GrubHub Earnings: Market Recon

If there was not a sizable addressable market for Beyond Meat, the competition would not be building as quickly as it is.

Jim Cramer: Demand Is Driving This Market to All-Time Highs

Jim Cramer: Demand Is Driving This Market to All-Time Highs

The stocks of many companies anticipated a more stringent series of tariffs and we didn't get them.

Arrowhead Pharmaceuticals Is Flying Higher on the Charts

Arrowhead Pharmaceuticals Is Flying Higher on the Charts

Before I give my recommendation I want to visit with the charts and indicators.

Real Money Post-Industrial Average Continues to Outpace Major Indices

Real Money Post-Industrial Average Continues to Outpace Major Indices

RMPIA is up 20.9% in the first nine months of 2019.

Jim Cramer: How to Survive This Violent Rotation

Jim Cramer: How to Survive This Violent Rotation

Emotions and panic must be checked at the door, if you are going to be a successful investor, especially right now.

Could Small Drug Trial Hold Big Potential for Amgen?

Could Small Drug Trial Hold Big Potential for Amgen?

The results of a lung-cancer drug got me to go long on the stock, but the larger picture is complicated.

Amgen's Lower Open Tests Support but the Bigger Picture Is More Important

Amgen's Lower Open Tests Support but the Bigger Picture Is More Important

Let's check out the charts to get a sense of where prices could be headed.

A Sagging Drugmaker and Lagging Pet Health Name Both Worth Looks

A Sagging Drugmaker and Lagging Pet Health Name Both Worth Looks

Alexion Pharmaceuticals and Elanco Animal Health have seen their shares go to the dogs of late, but still offer reasons for portfolio consideration.

Real Money Post-Industrial Average Holds Own in Turbulent August

Real Money Post-Industrial Average Holds Own in Turbulent August

Gains in Amgen, CVS, and others helped offset declines in other stocks, as the RMPIA rose over the last two months to 0.6%, handily beating all the major domestic stock market averages.

The Market Has Fury for a Suitor Scorned

Otezla Price Under Microscope -- but Look Closely and It Checks Out

Otezla Price Under Microscope -- but Look Closely and It Checks Out

Sure, Celgene, in its tie-up with Bristol-Myers Squibb, had to sell to meet merger requirements, but look at the future pay off for Amgen.

M&A Appetite in Pharma Has Proved Potent: Chart of the Day

M&A Appetite in Pharma Has Proved Potent: Chart of the Day

With total deals trending toward hundreds of billions, investors may be eager to bet on who's next to be acquired.

Amgen Charts Indicate Shares Want to Work Their Way Higher Longer Term

Amgen Charts Indicate Shares Want to Work Their Way Higher Longer Term

Amgen's deal to buy Otezla from Celgene should not deter the drugmaker's stock from gaining ground over the long haul.

Amgen Adds Celgene's Otezla to Bolster Pipeline at Pricey Valuation

Amgen Adds Celgene's Otezla to Bolster Pipeline at Pricey Valuation

Amgen is finally making an expected splash out of its cash pile, but questions are abounding about the cost paid for Celgene's Otezla.

A Pair of Rare Disease Biotech Concerns Worth a Good Look

A Pair of Rare Disease Biotech Concerns Worth a Good Look

Alexion Pharmaceuticals is a solid company that is the subject of acquisition rumors and Amicus Therapeutics has a key drug off to a strong start.

Fear Not the Curve, Sizing Up Earnings and Ways to Play Amgen: Market Recon

Fear Not the Curve, Sizing Up Earnings and Ways to Play Amgen: Market Recon

Understanding yourself and the investing environment you are in are keys to avoiding panic brought on by fear.

Real Money Post-Industrial Average Leads Major Indexes So Far for Year

Real Money Post-Industrial Average Leads Major Indexes So Far for Year

In July, the RMPIA climbed 0.6%, bringing its year-to-date return to just over 21%.